PMID- 25702674
OWN - NLM
STAT- MEDLINE
DCOM- 20150605
LR  - 20181202
IS  - 2038-2529 (Electronic)
IS  - 0300-8916 (Linking)
VI  - 101
IP  - 1
DP  - 2015 Jan-Feb
TI  - Bleeding after bevacizumab treatment in patients with metastatic colorectal 
      cancer.
PG  - 46-51
LID - 10.5301/tj.5000211 [doi]
AB  - AIMS AND BACKGROUND: To evaluate the adverse events (AEs) of bleeding caused by 
      bevacizumab/5-fluorouracil/leucovorin (5-FU/LV) combination chemotherapy with 
      addition of irinotecan or oxaliplatin in patients with metastatic colorectal 
      cancer (mCRC). METHODS: A retrospective study was conducted to evaluate the 
      bleeding AEs associated with bevacizumab and to explore potential associations 
      between bleeding and baseline patient characteristics. The National Cancer 
      Institute Common Terminology Criteria for Adverse Events v4.0 were used to 
      classify the severity of AEs. AEs were divided into five grades: grade 1, mild: 
      intervention not indicated; grade 2, moderate: medical intervention or minor 
      cauterization indicated; grade 3, severe: transfusion, radiological, endoscopic 
      or elective surgical intervention indicated; grade 4, life threatening: urgent 
      intervention indicated; and grade 5, death. RESULTS: Sixty-two patients were 
      evaluated. Bleeding occurred in 26 (41%) patients; the incidence of grade 3 
      bleeding was 1.6% while no grade 4-5 bleeding occurred. Grade 1 epistaxis and 
      grade 2 hemoptysis events were observed in 25.8% and 3.2% of patients, 
      respectively. Hematochezia events occurred in 12 (19.4%) patients, one (1.6%) of 
      whom required bevacizumab discontinuation. The incidence of hematochezia was 
      higher in patients with unresected primary tumors, prior intestinal bleeding, and 
      tumor response (p<0.05). CONCLUSIONS: These data provide important information 
      about the incidence of clinically significant bleeding AEs, including 
      minor mucocutaneous hemorrhage and major tumor-related bleeding such as 
      hemoptysis and hematochezia in bevacizumab-treated mCRC patients. In addition, 
      unresected primary tumor, prior bleeding, and tumor response were significant 
      risk factors for hematochezia.
FAU - Cao, Dan
AU  - Cao D
AD  - Department of Medical Oncology, Cancer Center, State Key Laboratory of 
      Biotherapy, West China Hospital, Sichuan University, Chengdu - China.
FAU - Guo, Chun-Hong
AU  - Guo CH
FAU - Liu, Jie-Wei
AU  - Liu JW
FAU - Yang, Xi
AU  - Yang X
FAU - Li, Qiu
AU  - Li Q
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150206
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage/*adverse effects
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Camptothecin/administration & dosage/analogs & derivatives
MH  - Colorectal Neoplasms/*drug therapy/*pathology
MH  - Epistaxis/chemically induced
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Hemoptysis/chemically induced
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Incidence
MH  - Irinotecan
MH  - Leucovorin/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Organoplatinum Compounds/administration & dosage
MH  - Oxaliplatin
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2015/02/24 06:00
MHDA- 2015/06/06 06:00
CRDT- 2015/02/24 06:00
PHST- 2014/08/08 00:00 [accepted]
PHST- 2015/02/24 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2015/06/06 06:00 [medline]
AID - B33A427C-088E-43DF-B552-D1EDB8AB76E4 [pii]
AID - 10.5301/tj.5000211 [doi]
PST - ppublish
SO  - Tumori. 2015 Jan-Feb;101(1):46-51. doi: 10.5301/tj.5000211. Epub 2015 Feb 6.